StockData
BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc. (BTAIQ) stock

BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30
$0.03−0.00 (-13.49%)

Close on Oct 19, 2026Market cap $757.50KP/E –Yield –

BioXcel Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

BioXcel Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$44.93M. For fiscal 2025 it was -$50.46M. The highest annual figure on record is -$4.54M in fiscal 2017.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$50.46M–
FY2024Dec 31, 2024-$67.25M–
FY2023Dec 31, 2023-$171.78M–
FY2022Dec 31, 2022-$159.65M–
FY2021Dec 31, 2021-$106.94M–
FY2020Dec 31, 2020-$82.30M–
FY2019Dec 31, 2019-$33.60M–
FY2018Dec 31, 2018-$19.96M–
FY2017Dec 31, 2017-$4.54M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$10.19M–
Q1 FY2026Mar 31, 2026-$10.22M–
Q4 FY2025Dec 31, 2025-$10.28M–
Q3 FY2025Sep 30, 2025-$14.23M–
Q2 FY2025Jun 30, 2025-$15.85M–
Q1 FY2025Mar 31, 2025-$10.10M–
Q4 FY2024Dec 31, 2024-$10.49M–
Q3 FY2024Sep 30, 2024-$15.29M–
Q2 FY2024Jun 30, 2024-$17.30M–
Q1 FY2024Mar 31, 2024-$24.16M–
Q4 FY2023Dec 31, 2023-$19.88M–
Q3 FY2023Sep 30, 2023-$48.30M–
Q2 FY2023Jun 30, 2023-$52.41M–
Q1 FY2023Mar 31, 2023-$51.20M–
Q4 FY2022Dec 31, 2022-$52.89M–
Q3 FY2022Sep 30, 2022-$38.99M–
Q2 FY2022Jun 30, 2022-$36.29M–
Q1 FY2022Mar 31, 2022-$31.48M–
Q4 FY2021Dec 31, 2021-$26.13M–
Q3 FY2021Sep 30, 2021-$26.81M–
Q2 FY2021Jun 30, 2021-$27.61M–
Q1 FY2021Mar 31, 2021-$26.38M–
Q4 FY2020Dec 31, 2020-$21.10M–
Q3 FY2020Sep 30, 2020-$24.77M–
Q2 FY2020Jun 30, 2020-$21.44M–
Q1 FY2020Mar 31, 2020-$15.00M–
Q4 FY2019Dec 31, 2019-$8.41M–
Q3 FY2019Sep 30, 2019-$9.13M–
Q2 FY2019Jun 30, 2019-$8.64M–
Q1 FY2019Mar 31, 2019-$7.42M–
Q4 FY2018Dec 31, 2018-$7.31M–
Q3 FY2018Sep 30, 2018-$5.12M–
Q2 FY2018Jun 30, 2018-$3.24M–
Q1 FY2018Mar 31, 2018-$4.29M–
Q4 FY2017Dec 31, 2017-$2.53M–
Q3 FY2017Sep 30, 2017-$917.00K–
Q2 FY2017Jun 30, 2017-$565.00K–
Q1 FY2017Mar 31, 2017-$529.00K–

More BioXcel Therapeutics figures

See a number that looks wrong?